DE69920949D1 - Ascomycin enthaltende topische zubereitungen - Google Patents

Ascomycin enthaltende topische zubereitungen

Info

Publication number
DE69920949D1
DE69920949D1 DE69920949T DE69920949T DE69920949D1 DE 69920949 D1 DE69920949 D1 DE 69920949D1 DE 69920949 T DE69920949 T DE 69920949T DE 69920949 T DE69920949 T DE 69920949T DE 69920949 D1 DE69920949 D1 DE 69920949D1
Authority
DE
Germany
Prior art keywords
ascomycin
topical preparations
containing topical
composition
topical administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69920949T
Other languages
English (en)
Other versions
DE69920949T2 (de
Inventor
Katrin Kriwet
Dorothea Ledergerber
Jutta Riedl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meda Pharma SARL
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of DE69920949D1 publication Critical patent/DE69920949D1/de
Publication of DE69920949T2 publication Critical patent/DE69920949T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69920949T 1998-12-03 1999-12-01 Ascomycin enthaltende topische zubereitungen Expired - Lifetime DE69920949T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9826656 1998-12-03
GBGB9826656.2A GB9826656D0 (en) 1998-12-03 1998-12-03 Organic compounds
PCT/EP1999/009351 WO2000032234A1 (en) 1998-12-03 1999-12-01 Topical compositions comprising ascomycins

Publications (2)

Publication Number Publication Date
DE69920949D1 true DE69920949D1 (de) 2004-11-11
DE69920949T2 DE69920949T2 (de) 2005-10-13

Family

ID=10843626

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69920949T Expired - Lifetime DE69920949T2 (de) 1998-12-03 1999-12-01 Ascomycin enthaltende topische zubereitungen

Country Status (28)

Country Link
US (3) US20010051650A1 (de)
EP (1) EP1135163B1 (de)
JP (1) JP3993745B2 (de)
KR (1) KR100514027B1 (de)
CN (1) CN1213767C (de)
AT (1) ATE278422T1 (de)
AU (1) AU767156B2 (de)
BR (1) BR9915861A (de)
CA (1) CA2350884C (de)
CZ (1) CZ301295B6 (de)
DE (1) DE69920949T2 (de)
DK (1) DK1135163T3 (de)
ES (1) ES2230905T3 (de)
GB (1) GB9826656D0 (de)
HK (1) HK1040362A1 (de)
HU (1) HU228742B1 (de)
IL (2) IL143093A0 (de)
NO (1) NO330576B1 (de)
NZ (1) NZ511687A (de)
PL (1) PL196628B1 (de)
PT (1) PT1135163E (de)
RU (1) RU2234319C2 (de)
SI (1) SI1135163T1 (de)
SK (1) SK285811B6 (de)
TR (1) TR200101547T2 (de)
TW (1) TWI245640B (de)
WO (1) WO2000032234A1 (de)
ZA (1) ZA200104529B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US20030050692A1 (en) * 2000-12-22 2003-03-13 Avantec Vascular Corporation Delivery of therapeutic capable agents
AUPR529701A0 (en) * 2001-05-28 2001-06-21 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical composition
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
US7442391B2 (en) * 2002-01-25 2008-10-28 Integrated Botanical Technologies, Llc Bioactive botanical cosmetic compositions and processes for their production
PE20030828A1 (es) * 2002-03-04 2003-11-04 Novartis Ag Composicion oftalmica que comprende ascomicina
GB0218996D0 (en) * 2002-08-14 2002-09-25 Novartis Ag Organic compounds
EP1594484A2 (de) * 2003-02-17 2005-11-16 Cipla Ltd. Pharmazeutisches pflaster
GB0307866D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
GB0408070D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Pharmaceutical formulations
ES2389443T3 (es) * 2004-04-08 2012-10-26 Meda Pharma S.À.R.L. Composición de espuma de pimecrolimus que contiene hexilenglicol, opcionalmente alcohol de oleílo, dimetilisosorbida y/o triglicéridos de cadena media
US7758901B2 (en) * 2007-02-16 2010-07-20 Betty Bellman Compositions and methods for alleviating skin disorders
DE102008006791B4 (de) * 2008-01-30 2011-11-24 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System mit Harnstoff-Komponente und Verfahren zu dessen Herstellung
KR101201956B1 (ko) 2009-03-18 2012-11-19 신동헌 파카스트리사민을 유효성분으로 함유하는 과증식성 피부질환과 악성흑색종의 예방 또는 치료용 약학적 조성물
JP7090549B2 (ja) * 2016-03-02 2022-06-24 ノヴァン，インコーポレイテッド 炎症のための治療用組成物およびその治療方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5799M (de) * 1966-03-22 1968-03-25
SE325667B (de) * 1968-03-06 1970-07-06 Medisan Ab
US4025310A (en) * 1976-05-28 1977-05-24 International Diagnostic Technology, Inc. Method for reading a wet fluorescent surface
DE2714601C2 (de) * 1977-04-01 1984-12-06 Skw Trostberg Ag, 8223 Trostberg Verfahren zur Herstellung eines Harnstoff-Dicyandiamid-Düngemittels
US4324811A (en) * 1980-04-17 1982-04-13 Stauffer Chemical Company Dough-like products exhibiting reduced water activity containing derived protein-containing compositions
KR830005852A (ko) * 1980-07-18 1983-09-14 미첼 페터 잭슨 피부와 점막의 비루스 감염치료에 적합한 국소치료제의 제조방법
DE3271532D1 (en) 1981-07-08 1986-07-10 Pfizer Salts of n-substituted-2-pyrrolidone-4-carboxylic acids as humectants
US4401650A (en) * 1981-09-15 1983-08-30 Thiokol Corporation Skin conditioning polymers containing alkoxylated nitrogen salts of sulfonic acid
AU548341B2 (en) * 1982-02-02 1985-12-05 Unilever Plc Acne treatment composition
JPS6013720A (ja) 1983-07-01 1985-01-24 Nitto Electric Ind Co Ltd 生理的活性剤の吸収促進剤
US4488989A (en) * 1983-11-14 1984-12-18 Lever Brothers Company Aqueous compositions containing urea as a hydrotrope
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
JPS60228423A (ja) 1984-04-26 1985-11-13 Nitto Electric Ind Co Ltd 基剤組成物および外用医薬組成物
US4672078A (en) * 1985-07-03 1987-06-09 Schering-Plough Corporation Urea stabilized with a lactone in various pharmaceutical and cosmetic preparations
US4690774A (en) * 1985-09-11 1987-09-01 Chesebrough Pond's Inc. Novel translucent water in oil emulsions
JPH0774144B2 (ja) 1986-03-12 1995-08-09 久光製薬株式会社 尿素を含有する皮膚用組成物
DE3612305A1 (de) * 1986-04-11 1987-10-22 Roehm Pharma Gmbh Fluessige arzneiform zur therapie der psoriasis auf basis filmbildender polymere
US5385938B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of using glycolic acid for treating wrinkles
CH677448A5 (de) 1987-11-09 1991-05-31 Sandoz Ag
AU630866B2 (en) 1987-12-09 1992-11-12 Fisons Plc Macrocyclic compounds
US5200190A (en) 1988-10-11 1993-04-06 Sekisui Kagaku Kogyo Kabushiki Kaisha Percutaneous pharmaceutical preparation
US4996193A (en) 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
FI104787B (fi) * 1989-06-07 2000-04-14 Xyrofin Oy Fruktoosipohjainen rakeistettu tuote ja menetelmä sen valmistamiseksi
US5002760A (en) * 1989-10-02 1991-03-26 Katzev Phillip K Retinol skin care composition
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
US5352671A (en) * 1989-11-09 1994-10-04 Sandoz Ltd. Heteroatoms-containing tricyclic compounds
EP0427680B1 (de) 1989-11-09 1995-08-23 Sandoz Ltd. Heteroatome enthaltende tricyclische Verbindungen
WO1991013899A1 (en) 1990-03-12 1991-09-19 Fujisawa Pharmaceutical Co., Ltd. Tricyclo compounds
IE910847A1 (en) 1990-03-13 1991-09-25 Fisons Plc Immunosuppressive macrocyclic compounds
EP0533930A1 (de) 1990-06-11 1993-03-31 Fujisawa Pharmaceutical Co., Ltd. Verwendung von einem makrolide sowie fk 506 zur herstellung von arzneimitteln für die behandlung von idiopathic thrombocytopenic purpura und basedow'schen krankheit
MY110418A (en) 1990-07-02 1998-05-30 Novartis Ag Heteroatoms-containing tricyclic compounds.
DK0474126T3 (de) * 1990-09-04 1997-04-07 Fujisawa Pharmaceutical Co
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
IE65341B1 (en) 1990-11-08 1995-10-18 Fujisawa Pharmaceutical Co Suspensions containing tricyclic compounds
JPH04182429A (ja) 1990-11-15 1992-06-30 Fujisawa Pharmaceut Co Ltd 非水溶液製剤
HU208491B (en) 1990-11-27 1993-11-29 Gyogyszerkutato Intezet Process for producing oral pharmaceutical composition containing cyclosporin
US5225403A (en) * 1991-06-25 1993-07-06 Merck & Co., Inc. C-21 hydroxylated FK-506 antagonist
JPH0525046A (ja) 1991-07-18 1993-02-02 Tanabe Seiyaku Co Ltd ニセルゴリン経皮吸収製剤
JPH0543457A (ja) 1991-08-08 1993-02-23 Sekisui Chem Co Ltd 経皮吸収製剤
US5252732A (en) 1991-09-09 1993-10-12 Merck & Co., Inc. D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity
US5247076A (en) 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
US5208241A (en) 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
HUT66531A (en) 1992-05-07 1994-12-28 Sandoz Ag Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them
DE4234225A1 (de) * 1992-10-10 1994-04-14 Roehm Pharma Gmbh Stabile topische Formulierungen mit gutem Wirkstoff-Freisetzungsvermögen enthaltend mindestens ein lipophilisiertes Makrolidantibiotikum
MY110603A (en) 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
JPH06345646A (ja) 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
DE4400770C1 (de) 1994-01-13 1995-02-02 Lohmann Therapie Syst Lts Wirkstoffhaltiges Pflaster zur Abgabe von Estradiol mit mindestens einem Penetrationsverstärker, Verfahren zu seiner Herstellung und seine Verwendung
JPH07252150A (ja) 1994-03-14 1995-10-03 T T S Gijutsu Kenkyusho:Kk オザグレル含有経皮吸収型製剤
JPH0834731A (ja) 1994-07-26 1996-02-06 T T S Gijutsu Kenkyusho:Kk グラニセトロン含有経皮吸収型製剤
JPH08133979A (ja) 1994-09-16 1996-05-28 Sando Yakuhin Kk 局所適用薬剤組成物
IL129547A (en) 1994-10-26 2001-01-11 Novartis Ag Pharmaceutical compositions comprising a macrolide and an acid
ATE214593T1 (de) * 1994-10-26 2002-04-15 Novartis Erfind Verwalt Gmbh Verwendung eines ungesättigten fettalkohols
JPH08143458A (ja) 1994-11-17 1996-06-04 Sekisui Chem Co Ltd 経皮吸収貼付剤
JPH08231369A (ja) 1995-02-20 1996-09-10 Shiseido Co Ltd 化粧料
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
HUP9801745A3 (en) 1995-05-31 2000-04-28 Schering Ag Sorbic-acid-containing hydrogels
JPH11512096A (ja) 1995-08-24 1999-10-19 メルク エンド カンパニー インコーポレーテッド イミダゾリルマクロライド免疫抑制剤の製造方法
JP2920611B2 (ja) 1995-12-11 1999-07-19 株式会社シーエーシー 皮膚炎の治療外用剤
DE19549243A1 (de) 1995-12-21 1997-06-26 Schering Ag Pharmazeutische Präparate enthaltend Clathrate von Cyclodextrinen und nichtnatürliche Vitamin D-Analoga
DE19606355A1 (de) 1996-02-12 1997-08-14 Schering Ag Kontrazeptive Freisetzungssysteme mit antiviraler und/oder antibakterieller Wirkung
JPH09315954A (ja) 1996-05-30 1997-12-09 Kita:Kk 眼科手術後の眼組織混濁防止剤。
EP0929227A1 (de) * 1996-09-05 1999-07-21 The Pillsbury Company Schmackhafte käsefüllungen und lebensmittel, welche diese füllungen enthalten
JPH10231248A (ja) 1997-02-19 1998-09-02 T T S Gijutsu Kenkyusho:Kk ジヒドロエトルフィン含有経皮吸収型製剤
JPH10251137A (ja) 1997-03-14 1998-09-22 Advanced Sukin Res Kenkyusho:Kk 光線過敏症抑制剤
GB9713730D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
KR20060066753A (ko) 1997-10-22 2006-06-16 젠스 포니카우 진균류에 의한 점막염을 국소 치료하기 위한 항진균제의용도
GB9723669D0 (en) 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
US6113892A (en) * 1997-12-23 2000-09-05 Helene Curtis, Inc. Compositions for cleansing, conditioning and moisturizing hair and skin
US5981464A (en) * 1998-01-26 1999-11-09 Lever Brothers Company, Division Of Conopco, Inc. Adjuvant composition
EP0937453A3 (de) * 1998-01-26 2000-04-19 Sam Schwartz Kosmetische, waschende und/oder befeuchtende Zusammensetzung
ATE363275T1 (de) 1998-04-27 2007-06-15 Astellas Pharma Inc Pharmazeutische gelformulierung enthaltend eine trizyklische substanz (fk-506/tacrolimus)
GB9814640D0 (en) 1998-07-06 1998-09-02 Fujisawa Pharmaceutical Co New use
US6124362A (en) * 1998-07-17 2000-09-26 The Procter & Gamble Company Method for regulating hair growth

Also Published As

Publication number Publication date
AU767156B2 (en) 2003-10-30
SK7622001A3 (en) 2001-11-06
HUP0104413A2 (hu) 2002-03-28
PL196628B1 (pl) 2008-01-31
DE69920949T2 (de) 2005-10-13
US20120202841A1 (en) 2012-08-09
KR100514027B1 (ko) 2005-09-13
RU2234319C2 (ru) 2004-08-20
CA2350884C (en) 2007-07-03
HK1040362A1 (en) 2002-06-07
EP1135163B1 (de) 2004-10-06
US20010051650A1 (en) 2001-12-13
PT1135163E (pt) 2005-02-28
PL348750A1 (en) 2002-06-03
EP1135163A1 (de) 2001-09-26
HUP0104413A3 (en) 2003-12-29
BR9915861A (pt) 2001-08-21
AU1656900A (en) 2000-06-19
JP3993745B2 (ja) 2007-10-17
JP2002531419A (ja) 2002-09-24
CZ301295B6 (cs) 2010-01-06
TWI245640B (en) 2005-12-21
CZ20011908A3 (cs) 2001-09-12
ZA200104529B (en) 2002-06-04
US20060058279A1 (en) 2006-03-16
NO20012624D0 (no) 2001-05-29
NZ511687A (en) 2003-10-31
KR20010080663A (ko) 2001-08-22
TR200101547T2 (tr) 2001-10-22
US9402802B2 (en) 2016-08-02
IL143093A0 (en) 2002-04-21
WO2000032234A1 (en) 2000-06-08
IL143093A (en) 2007-05-15
GB9826656D0 (en) 1999-01-27
NO330576B1 (no) 2011-05-16
ATE278422T1 (de) 2004-10-15
SI1135163T1 (en) 2005-04-30
HU228742B1 (en) 2013-05-28
CN1213767C (zh) 2005-08-10
CA2350884A1 (en) 2000-06-08
ES2230905T3 (es) 2005-05-01
DK1135163T3 (da) 2005-01-31
NO20012624L (no) 2001-07-09
SK285811B6 (sk) 2007-08-02
CN1329507A (zh) 2002-01-02

Similar Documents

Publication Publication Date Title
DE69920949D1 (de) Ascomycin enthaltende topische zubereitungen
FR2631235B1 (fr) Compositions de cyclosporine pour application topique
DE69624812T2 (de) Verringerung des mehrwegeffekts in gps-empfängern
DE69815585D1 (de) topische Zubereitung enthaltend Phosphatpuffer als Hautdurchlässigkeitverstärker
TR200100922T2 (tr) Aktif maddelerin akciğerler yolu ile tatbik edilmesi.
ID22878A (id) Komposisi aktif secara terapi
TR199802423T2 (xx) Konsantre antikor terkibi.
AU4460900A (en) Carrier patch for the delivery of agents to the skin
EE200000595A (et) Toimeaine viimine kandjamaatriksisse
DE69831017D1 (de) Zubereitungen zur topischen anwendung, die ascorbyl-phosphoryl-cholesterol enthalten
ZA964552B (en) Compositions for topical application to skin.
ZA200102836B (en) Derivatives of isosorbid mononitrate, utilization as vasodilator agents with reduced tolerance.
IT1287174B1 (it) Diaril-ciclometilenpirazoli farmacologicamente attivi,procedimento per prepararli e composizioni farmaceutiche che li contengono
GB2343844A8 (en) Topical therapeutic composition comprising an enzyme
ITTO950607A0 (it) Composizione farmaceutica per uso topico
TR199901232T2 (xx) Canl� organizmalara peptitli farmakonlar�n verilmesi i�in lokal terkip.
MY126730A (en) Topical compositions comprising ascomycins
ITGE920060A0 (it) Soluzione sclerosante, ad elevata efficacia, che non produce lesioni iatrogene e procedimento per ottenere tale soluzione.
ATE397615T1 (de) 6-o-alkyl-2-nor-2-substituierte ketolidderivate
FR2717391B1 (fr) Peptides pour inhiber la libération de pepsine.
IT1306187B1 (it) Metodo per l'eradicazione selettiva di cellule tumorali aventi lafunzione di p53 inattiva.
ZA996444B (en) Composition to enhance skin premeation of topical skin agents.
ZA983243B (en) Novel aryl compounds, processes for their preparation, pharmacological compositions containing the same and their use in therapy.
FI960435A0 (fi) Lääkkeiden transdermaalisen antotapaan tarkoitettuLääkkeiden transdermaalisen antotapaan tarkoitettu koostumus koostumus
CA2458872A1 (en) Human ubiquitin-conjugating enzyme

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN

R082 Change of representative

Ref document number: 1135163

Country of ref document: EP

Representative=s name: DR. SCHOEN & PARTNER, DE

R081 Change of applicant/patentee

Ref document number: 1135163

Country of ref document: EP

Owner name: MEDA PHARMA S.A.R.L., LU

Free format text: FORMER OWNER: NOVARTIS AG, 4056 BASEL, CH

Effective date: 20121128

R082 Change of representative

Ref document number: 1135163

Country of ref document: EP

Representative=s name: DR. SCHOEN & PARTNER, DE

Effective date: 20121128